5,000+ Healthcare Facilities Reached Through
GPO Agreements, Covering ~60% of Institutional GPO Market
U.S. naloxone market totals ~$144 million in annual sales and ~9.8 million units annually,
represents significant commercial opportunity for REZENOPY™